IIBBA   05544
INSTITUTO DE INVESTIGACIONES BIOQUIMICAS DE BUENOS AIRES
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
RMN METABOLIC PROFILING FOR THE DISCOVERY OF NEW PUTATIVE BIOMARKERS FOR ALZHEIMER?S DISEASE IN A RAT MODEL
Autor/es:
MARTÍN ARAN; CARINA C. FERRARI; LAURA MORELLI; CAROLINA DALMASSO; CLARA SMAL
Lugar:
Rosario
Reunión:
Simposio; 2nd Latin American Metabolic Profiling Symposium; 2016
Resumen:
Alzheimer?s Disease (AD) is the most common form of elderly associated dementia, affecting ~46 million people worldwide. Moreover, most people with dementia have not received a formal diagnosis, and therefore do not have access to treatment, care and organized support. AD starts many years before symptoms appear, defining a presymptomatic stage. A good detection method of this period will provide future patients the opportunity to plan their future, and conduct a preventive behavior to delay the appearance of dementia. Thus our main goal is to perform untargeted NMR metabolomics in an animal model for presymptomatic AD, in order to identify relevant metabolites that could be used as biomarkers for early diagnosis of the disease. To this aim, we use the transgenic hemizygous rat model McGill-R-Thy1-APP (TG+/-). Experiments were performed in male TG+/- and non-transgenic littermate (WT) rats of 9 months of age; conditions that has been well characterized in our laboratory (1, 2). From each animal, CSF and hippocampus were collected to study changes at brain level, and plasma to study changes at systemic level. Samples were processed and analyzed as described Beckonert O. et. al. (3). In contrast to hippocampus and plasma, CSF samples were hard to obtain, often CSF of more than one animal should be pooled to reach detection volume, and they were usually contaminated with plasma, questioning the suitability of CSF samples to our goal. Preliminary results observed by Pincipal Component Analysis (PCA) performed on 1D H-RMN results, suggest that metabolic changes occurring in TG+/- rats are more evident in plasma than hippocampus at early stages of the disease (Figure1). Efforts to identify metabolic changes occuring in TG+/- are being carried out.